Cytomegalovirus Disease: Hemopoietic Recovery and Immune Control of Pulmonary Infection After Bone Marrow Transplantation

  • M. J. Reddehase
Conference paper


Cytomegaloviruses (CMV) are grouped into the beta-subfamily of the Herpesviridae. The beta-herpesviruses are all strictly species-specific. The viral genome is a double-stranded linear DNA of ca. 230 kbp. With ca. 200 open reading frames it represents the highest coding capacity known for viruses (Mocarski 1993). The infectious virus particle, the virion, is composed of a DNA nucleoprotein core, an icosahedral capsid, a tegument and, as the outer frontier, an envelope, which contains several glycoproteins for its interaction with host cells permissive for infection. Human CMV is the prototype and is of clinical relevance. Murine CMV shows homologies, but also differences at the levels of genetic organisation, DNA sequence, and proteins. Despite the differences, as far as we can judge to date, the pathogenesis and characteristics of disease are fairly similar for the two viruses. Murine CMV infection has therefore been employed as an experimental model to study CMV pathogenesis in the immunocompromised host and the principles of immune control of the infection in the immunocompetent host (Koszinowski et al. 1990,1993).


Cytomegalovirus Infection Bone Marrow Transplantation Recipient Cytomegalovirus Disease Femoral Bone Marrow Antigenemia Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Apperley JF, Dowding C, Hibbin J, Buiter J, Matutes E, Sissons PJ, Gordon M, Goldman JM (1989) The effect of cytomegalovirus on hematopoiesis: in vitro evidence for selective infection of marrow stromal cells. Exp Hematol 17:38–45PubMedGoogle Scholar
  2. Balthesen M, Messerle M, Reddehase MJ (1993) Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 67:5360–5366PubMedGoogle Scholar
  3. Balthesen M, Dreher L, Lucin P, Reddehase MJ (1994) The establishment of cytomegalovirus latency in organs is not linked to local virus production during primary infection. J Gen Virol 75:2329–2336PubMedCrossRefGoogle Scholar
  4. Busch FW, Mutter W, Koszinowski UH, Reddehase MJ (1991) Rescue of myeloid lineage-committed preprogenitor cells from cytomegalovirus-infected bone marrow stroma. J Virol 65:981–984PubMedGoogle Scholar
  5. Childs B, Emanuel D (1993) Cytomegalovirus infection and compromise. Exp Hematol 21:198–200PubMedGoogle Scholar
  6. Einsele H, Ljungman P (1993) New developments in the diagnosis, prophylaxis and therapy of cytomegalovirus infection in marrow transplant recipients. Bone Marrow Transplant 12 Suppl 4:85–87Google Scholar
  7. Forman SJ, Zaia JA (1994) Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood 83:2392–2398PubMedGoogle Scholar
  8. Hertenstein B, Hampl W, Bunjes D, Wiesneth M, Dunker C, Koszinowski UH, Heimpel H, Arnold R, Mertens T (1995) Impact of graft versus host disease prophylaxis by in vivo/ex vivo T cell depletion on cytomegalovirus infection and disease early after bone marrow transplantation. Bone Marrow Transplant (in press)Google Scholar
  9. Keller G (1992) Clonal analysis of hematopoietic stem cell development in vivo. Curr Top Microbiol Immunol 177:41–57PubMedCrossRefGoogle Scholar
  10. Koszinowski UH, Del Val M, Reddehase MJ (1990) Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr Top Microbiol Immunol 154:189–220PubMedCrossRefGoogle Scholar
  11. Koszinowski UH, Reddehase MJ, Jonjic S (1993) The role of T-lymphocyte subsets in the control of cytomegalovirus infection. In: Thomas DB (ed) Viruses and the cellular immune response. Dekker, New York, pp 429–445Google Scholar
  12. Ljungman P, Einsele H (1995) Cytomegalovirus infection. Curr Opin Hematol (in press)Google Scholar
  13. Ljungman P, Griffiths P (1993) Definitions of cytomegalovirus infection and disease. Excerpta Med Int Congr Ser 1032:233–237Google Scholar
  14. Ljungman P, Engelhard D, Link H, Biron P, Brandt L, Brunet S, Cordonnier C, Debusscher L, De Laurenzi A, Kolb HJ, Messina C, Newland AC, Prentice HG, Richard C, Ruutu T, Tilg H, Verdonck L (1992) Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European bone marrow transplant group. Clin Infect Dis 14:831–835PubMedCrossRefGoogle Scholar
  15. Meyers J, Flournoy N, Thomas ED (1986) Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153:478–488PubMedCrossRefGoogle Scholar
  16. Mocarski ES (1993) Cytomegalovirus biology and replication. In: Roizman B, Whitley RJ, Lopez C (eds) The human herpesviruses. Raven, New York, pp 173–226Google Scholar
  17. Mocarski ES, Abenes GB, Manning WC, Sambucetti LC, Cherrington JM (1990) Molecular genetic analysis of cytomegalovirus gene regulation in growth, persistence and latency. Curr Top Microbiol Immunol 154:47–74PubMedCrossRefGoogle Scholar
  18. Mutter W, Reddehase MJ, Busch FW, Bühring HJ, Koszinowski UH (1988) Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompomised host. J Exp Med 167:1645–1658PubMedCrossRefGoogle Scholar
  19. Reddehase MJ, Weiland F, Münch K, Jonjic S, Lüske A, Koszinowski UH (1985) Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol 55:264–273PubMedGoogle Scholar
  20. Reddehase MJ, Mutter W, Koszinowski UH (1987) In vivo application of recombinant interleukin-2 in the immunotherapy of established cytomegalovirus infection. J Exp Med 165:650–656PubMedCrossRefGoogle Scholar
  21. Reddehase MJ, Rothbard JB, Koszinowski UH (1989) A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature 337: 651–653PubMedCrossRefGoogle Scholar
  22. Reddehase MJ, Balthesen M, Rapp M, Jonjic S, Pavic I, Koszinowski UH (1994) The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 179:185–193PubMedCrossRefGoogle Scholar
  23. Reusser P, Riddell S, Meyers J, Greenberg PD (1991) Cytotoxic T lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373–1380PubMedGoogle Scholar
  24. Riddell SR, Watanabe K, Goodrich J, Li CR, Agha M, Greenberg PD (1992) Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science 257:238–241PubMedCrossRefGoogle Scholar
  25. Schmidt C, Oettle H, Wilborn P, Jessen J, Timm H, Schwerdfeger R, Oertel J, Siegert W (1994) Demonstration of cytomegalovirus after bone marrow transplantation by polymerase chain reaction, virus culture and antigen detection in buffy coat leukocytes. Bone Marrow Transplant 13:71–75PubMedGoogle Scholar
  26. Simmons P, Kaushansky K, Torok-Storb B (1990) Mechanisms of cytomegalovirus- mediated myelosuppression: perturbation of stromal cell function versus direct infection of myeloid cells. Proc Natl Acad Sci USA 87:1386–1390PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • M. J. Reddehase

There are no affiliations available

Personalised recommendations